Cancer stem cells (CSCs) are a subpopulation of tumor cells with the ability to self-renew, differentiate, and initiate new tumors. In pancreatic ductal adenocarcinoma, CSCs are thought to be responsible for treatment resistance, metastasis, and disease recurrence after chemotherapy.
CSCs are typically identified by the expression of specific surface markers. In pancreatic cancer, commonly used markers include CD24, CD44, and EpCAM. Cells expressing these markers demonstrate enhanced tumor-initiating capacity in transplantation assays and greater resistance to gemcitabine and other standard therapies.
MicroRNAs (miRNAs) regulate gene expression post-transcriptionally by targeting messenger RNAs for degradation or translational repression. Because of their broad regulatory influence over thousands of target genes, miRNAs are well positioned to control the balance between CSC and non-CSC states within a tumor.
Identifying miRNAs that specifically suppress CSC properties could reveal new therapeutic targets. Restoring the expression of CSC-suppressive miRNAs, or silencing CSC-promoting miRNAs, might reduce tumor-initiating capacity and improve the effectiveness of standard cytotoxic therapies.
The study used two well-characterized pancreatic cancer cell lines: MIA PaCa-2 and PANC-1. These lines differ in their molecular characteristics and represent different aspects of PDAC biology, making them a useful pair for identifying miRNAs associated with stemness differences.
Global miRNA expression profiling was performed using microarray technology, comparing the full miRNA transcriptome between the two cell lines. This unbiased approach identified all miRNAs differentially expressed between the lines without requiring prior hypotheses about which miRNAs might be important.
CSC content was quantified by flow cytometry using antibodies against CD24, CD44, and EpCAM surface markers. The proportion of cells expressing each marker individually and in combination was measured to establish which cell line had a higher baseline CSC frequency.
To test whether specific miRNAs functionally suppress CSC properties, miRNA mimics (synthetic double-stranded RNA molecules that replicate the activity of mature miRNAs) were transfected into cells. The effects on CSC marker expression and sphere-forming ability were then measured to assess functional CSC suppression.
Sphere formation assays were used as a functional test of stemness. Cancer stem cells can survive and proliferate in non-adherent suspension conditions to form floating spheres, and the number and size of spheres formed is a quantitative measure of CSC frequency and self-renewal capacity.
Microarray profiling identified 33 differentially expressed miRNAs between MIA PaCa-2 and PANC-1 cells. Of these, 18 were upregulated and 15 were downregulated in PANC-1 relative to MIA PaCa-2, providing a shortlist of candidates potentially linked to stemness differences.
PANC-1 cells demonstrated significantly higher CSC marker expression compared to MIA PaCa-2. Specifically, PANC-1 cells showed 9.8% CD24-positive, 36.6% EpCAM-positive, and 7.2% triple-positive (CD24+/CD44+/EpCAM+) fractions, indicating a substantially larger CSC pool than MIA PaCa-2.
From the 33 differentially expressed candidates, three miRNAs were selected for functional validation based on their degree of differential expression and known biological context: miR-7-5p, let-7d, and miR-135b-5p. All three were expressed at lower levels in the higher-stemness PANC-1 line, consistent with a CSC-suppressive role.
When miRNA mimics for each of the three candidates were transfected into PANC-1 cells, CSC surface marker expression was reduced by approximately 50%. Sphere formation capacity was similarly impaired, confirming that these miRNAs functionally suppress CSC properties when their levels are restored.
miR-7-5p is known to target multiple oncogenic pathways including the EGFR/PI3K/AKT signaling axis and IGF1R. Suppression of these growth factor receptor pathways by miR-7-5p could reduce the survival and proliferative advantages that characterize CSCs.
let-7d belongs to the let-7 family, one of the first miRNAs discovered and among the most studied in cancer biology. let-7 family members are widely recognized as tumor suppressors that target oncogenes such as RAS and HMGA2. Reduced let-7 expression is associated with poor prognosis in many cancers including PDAC.
miR-135b-5p has been studied in the context of cancer stem cell regulation in other cancers, where it modulates Wnt/beta-catenin signaling and targets genes involved in epithelial-mesenchymal transition (EMT). EMT is a process that increases cell plasticity and CSC characteristics.
The convergence of these three miRNAs on multiple key stemness-associated pathways suggests that their combined downregulation in high-CSC-content pancreatic cancer cells is not coincidental but represents a concerted loss of regulatory control over the CSC state.
The identification of miRNAs that suppress CSC properties suggests a potential therapeutic strategy of miRNA replacement therapy: delivering synthetic miRNA mimics or viral vectors encoding CSC-suppressive miRNAs into tumors to reduce the proportion of treatment-resistant stem-like cells.
Combining miRNA-based CSC suppression with standard chemotherapy could address one of the main drivers of PDAC treatment failure. If CSC-suppressive miRNAs sensitize tumor cells to gemcitabine or FOLFIRINOX, the combination might achieve deeper and more durable responses than chemotherapy alone.
Blood-based measurement of circulating miRNAs could serve a diagnostic or monitoring function. If miR-7-5p, let-7d, or miR-135b-5p levels in patient plasma reflect tumor CSC content, they might serve as non-invasive biomarkers of stemness, treatment resistance risk, or early relapse.
The main translational challenge is delivering miRNA mimics efficiently to tumor cells in vivo. Lipid nanoparticle formulations and other delivery vehicles are being actively investigated to improve the bioavailability and tumor specificity of miRNA-based therapeutics.
This study identified three CSC-suppressive miRNAs (miR-7-5p, let-7d, and miR-135b-5p) in pancreatic cancer cell lines through a systematic comparison of miRNA expression profiles between cell lines with different CSC content. Functional validation confirmed that restoring these miRNAs reduces CSC marker expression and impairs self-renewal.
The findings extend the growing evidence that miRNA dysregulation is a key mechanism by which pancreatic cancer cells acquire and maintain the CSC phenotype. Therapeutic strategies targeting this regulatory layer represent a complementary approach to conventional cytotoxic therapy.
Future studies should move beyond cell lines to primary patient-derived organoids and in vivo xenograft models to assess whether miRNA mimic delivery reduces CSC content and improves chemotherapy responses in more physiologically relevant systems.
Ultimately, the goal is to translate these findings into clinical biomarker assays for patient stratification and, longer term, into miRNA-based therapeutic interventions that reduce treatment resistance and improve survival for PDAC patients.